DelveInsight’s “Neurofibromatosis Type 2 Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Neurofibromatosis Type 2 pipeline landscape. It covers the Neurofibromatosis Type 2 Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neurofibromatosis Type 2 Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Neurofibromatosis Type 2 Pipeline? @ https://www.delveinsight.com/sample-request/neurofibromatosis-2-pipeline-insight
Key Takeaways from the Neurofibromatosis Type 2 Pipeline Report
- On April 08, 2026, SpringWorks Therapeutics Inc. initiated a phase 2b study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.
- On April 07, 2026, the Alliance for Clinical Trials in Oncology announced a phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- DelveInsight’s Neurofibromatosis Type 2 Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Neurofibromatosis Type 2 treatment.
- The leading Neurofibromatosis Type 2 Companies such as AstraZeneca, Recursion Pharmaceuticals, Betta Pharmaceuticals Co. Ltd., Novartis Pharmaceuticals, Genentech, Takeda and others.
- Promising Neurofibromatosis Type 2 Therapies such as Everolimus (RAD001) , Afinitor®, AZD2014, Lapatinib, HLX-1502, Icotinib, Endostatin, Bevacizumab, Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Brigatinib, Neratinib and others.
Want to know which companies are leading innovation in Neurofibromatosis Type 2? @ Neurofibromatosis Type 2 Clinical Trials Assessment
The Neurofibromatosis Type 2 Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Neurofibromatosis Type 2 Pipeline Report also highlights the unmet needs with respect to the Neurofibromatosis Type 2.
Neurofibromatosis Type 2 Overview
Neurofibromatosis 2 (NF2) is a rare genetic disorder that is primarily characterized by noncancerous (benign) tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain (bilateral acoustic neuromas/vestibular schwannomas). Symptoms may become apparent during childhood, adolescence, and early adulthood or later in adult life. Depending on the exact location and size of the acoustic neuromas/vestibular schwannomas, or other schwannomas such findings may include problems with balance and walking (gait); dizziness; headache; facial weakness, numbness, or pain; but more typically ringing in the ears (tinnitus); and/or progressive hearing loss. In some individuals with NF2, additional abnormalities may be present. These may include clouding of the lenses of the eyes (juvenile posterior subcapsular opacities), progressive visual impairment, or an increased risk of developing certain tumors of the lining of the brain (meningiomas) and spinal cord (central nervous system).
Neurofibromatosis Type 2 Emerging Drugs Profile
- Selumetinib: AstraZeneca
Selumetinib is a MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib is a non-ATP-competitive mitogen-activated protein kinase kinase 1 and 2 (MEK1 and MEK2) inhibitor. By selectively targeting MEK1 and MEK2, selumetinib is able to inhibit oncogenic downstream effects of the Raf-MEK-ERK signaling pathway, which is often overactive in certain types of cancer. Currently, it is in Phase II stage of clinical trial evaluation to treat Neurofibromatosis Type II Related Tumors.
- REC-2282: Recursion Pharmaceuticals
REC-2282 is a potentially first-in-class, orally bioavailable, CNS-penetrant small molecule HDAC inhibitor being developed for the treatment of NF2-mutated meningiomas. The U.S. Food and Drug Administration (FDA) had granted the company Fast Track designation for the investigation of REC-2282 for treatment of patients with NF2-mutated meningiomas, including neurofibromatosis type-2 disease-related meningiomas.
If you’re tracking ongoing Neurofibromatosis Type 2 Clinical trials @ Neurofibromatosis Type 2 Treatment Drugs
The Neurofibromatosis Type 2 Pipeline report provides insights into:-
- The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibromatosis Type 2 with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibromatosis Type 2 Treatment.
- Neurofibromatosis Type 2 Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Neurofibromatosis Type 2 Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibromatosis Type 2 market.
Neurofibromatosis Type 2 Companies
AstraZeneca, Recursion Pharmaceuticals, Betta Pharmaceuticals Co. Ltd., Novartis Pharmaceuticals, Genentech, Takeda and others.
Neurofibromatosis Type 2 Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Neurofibromatosis Type 2 Products have been categorized under various Molecule types such as,
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
From emerging drug candidates to competitive intelligence, the Neurofibromatosis Type 2 Pipeline Report @ Neurofibromatosis Type 2 Market Drivers and Barriers, and Future Perspectives
Scope of the Neurofibromatosis Type 2 Pipeline Report
- Coverage- Global
- Neurofibromatosis Type 2 Companies- AstraZeneca, Recursion Pharmaceuticals, Betta Pharmaceuticals Co. Ltd., Novartis Pharmaceuticals, Genentech, Takeda and others.
- Neurofibromatosis Type 2 Therapies- Everolimus (RAD001) , Afinitor®, AZD2014, Lapatinib, HLX-1502, Icotinib, Endostatin, Bevacizumab, Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Brigatinib, Neratinib and others.
- Neurofibromatosis Type 2 Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Neurofibromatosis Type 2 Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discover what’s next for the Neurofibromatosis Type 2 Treatment landscape in this detailed analysis @ Neurofibromatosis Type 2 Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Neurofibromatosis Type 2: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Neurofibromatosis Type 2– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II)
- Selumetinib: AstraZeneca
- Early Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Inactive Products
- Neurofibromatosis Type 2 Key Companies
- Neurofibromatosis Type 2 Key Products
- Neurofibromatosis Type 2- Unmet Needs
- Neurofibromatosis Type 2- Market Drivers and Barriers
- Neurofibromatosis Type 2- Future Perspectives and Conclusion
- Neurofibromatosis Type 2 Analyst Views
- Neurofibromatosis Type 2 Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/neurofibromatosis-2-pipeline-insight